Endocannabinoids: a new class of vasoactive substances

Trends in Pharmacological Sciences
Michael D Randall, David A Kendall

Abstract

Endogenous cannabinoids (endocannabinoids) have recently been identified in the CNS and attention has now turned to their cardiovascular actions. The prototypic endocannabinoid, anandamide, derived from arachidonic acid, has been shown to be a vasorelaxant, particularly in the resistance vasculature. This vasorelaxation has been shown to be both endothelium-independent and -dependent, depending on the vascular bed. It has been proposed that an endocannabinoid may mediate the nitric oxide- and prostanoid-independent component of endothelium-dependent relaxations, as these responses are sensitive to a cannabinoid receptor antagonist and show similarities to anandamide-induced relaxations. This hypothesis has generated much controversy and the emerging conflicts in the literature are discussed in this article by Michael Randall and David Kendall. Despite this controversy, it has recently been shown that anandamide is produced by endothelial cells. Clearly, much work is required to adequately define the physiological significance of endocannabinoids in the cardiovascular system.

References

May 29, 1992·Journal of Medicinal Chemistry·W A DevaneR Mechoulam
Aug 1, 1988·Trends in Pharmacological Sciences·S G Taylor, A H Weston
Dec 1, 1995·Circulation·R A Cohen, P M Vanhoutte
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·L FacciA Leon
Jan 1, 1995·Trends in Pharmacological Sciences·C J GarlandT M Cocks
Mar 17, 1995·The Journal of Biological Chemistry·F DesarnaudD Piomelli
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·W A Devane, J Axelrod
Sep 1, 1993·Biochemical Pharmacology·D G Deutsch, S A Chin
Oct 1, 1993·Journal of Medicinal Chemistry·L HanusR Mechoulam
Jul 1, 1996·British Journal of Pharmacology·P M ZygmuntE D Högestätt
Oct 25, 1996·Journal of Medicinal Chemistry·A D KhanolkarA Makriyannis
May 1, 1997·British Journal of Pharmacology·P M ZygmuntE D Högestätt
Sep 18, 1997·The Journal of Clinical Investigation·D G DeutschL C Moore

❮ Previous
Next ❯

Citations

Mar 31, 2005·Microvascular Research·Ping ChenXiang Fang
Dec 7, 2000·Chemistry and Physics of Lipids·H S HansenG Petersen
Dec 7, 2000·Chemistry and Physics of Lipids·G KunosJ A Wagner
Oct 6, 2000·European Journal of Pharmacology·I R Hutcheson, T M Griffith
Mar 29, 2001·European Journal of Pharmacology·S KagotaM Kunitomo
Oct 24, 2001·European Journal of Pharmacology·V RalevicD Smart
May 15, 2002·European Journal of Pharmacology·Maria Michela CainazzoSalvatore Guarini
Jun 14, 2002·European Journal of Pharmacology·Vera Ralevic, David A Kendall
Nov 27, 1998·European Journal of Pharmacology·R MechoulamV Di Marzo
Jan 27, 1999·European Journal of Pharmacology·M Beltramo, D Piomelli
Apr 29, 2000·Prostaglandins & Other Lipid Mediators·V Di MarzoT Bisogno
Apr 29, 2000·Prostaglandins & Other Lipid Mediators·G KunosJ A Wagner
Jun 15, 1999·Prostaglandins & Other Lipid Mediators·C FimianiG B Stefano
Jul 13, 2001·Pharmacology & Therapeutics·A C Porter, C C Felder
Jan 9, 1999·Trends in Neurosciences·V Di MarzoL De Petrocellis
Nov 7, 1998·British Journal of Pharmacology·R White, C R Hiley
Apr 27, 1999·British Journal of Pharmacology·N Niederhoffer, B Szabo
May 14, 1999·British Journal of Pharmacology·J V MombouliW F Graier
Apr 13, 2000·The European Journal of Neuroscience·A PorcellaL Pani
Oct 20, 1998·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·F M Faraci, C G Sobey
Apr 8, 2006·Clinical Chemistry and Laboratory Medicine : CCLM·Michael VogeserGustav Schelling
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·Z JáraiG Kunos
Feb 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Garry MilmanRaphael Mechoulam
Jan 19, 2005·Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi·Yoshio TanakaLigia Toro
Sep 22, 2009·Prostaglandins & Other Lipid Mediators·Y S WeemsC W Weems
Aug 26, 2010·British Journal of Pharmacology·Alexander BondarenkoWolfgang F Graier
Apr 24, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·Leila Moezi, Ahmad R Dehpour
Mar 23, 2011·British Journal of Pharmacology·Esther ShohamiRaphael Mechoulam
Jul 11, 2006·European Journal of Pharmacology·Mehdi GhasemiAhmad Reza Dehpour
Apr 6, 2007·The European Journal of Neuroscience·Zachary NewmanClark Lindgren
Sep 12, 2007·Liver International : Official Journal of the International Association for the Study of the Liver·Ying-Ying YangShou-Dong Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Homeostasis

Cardiovascular regulation and homeostasis is important in maintaining health and dysfunction may lead to cardiovascular diseases. Nitric oxide and vascular endothelium are one of many molecules involved in the homeostatic mechanism. Here is the latest research on cardiovascular homeostasis.